Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Michael Goggins

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4286-2296; OpenAlex author ID A5090286753; NIH RePORTER profile ID 7060159. Sources: funder_awards.

Their work

Papers
141 (first author 5, last author 45)
Trials
1 (principal investigator on 1)
Grants
5
Labs led
1
Collaborators
408
Papers, trials and grants by year

2011: 7 papers · 2012: 7 papers · 2013: 9 papers, 1 grant · 2014: 4 papers, 1 trial · 2015: 7 papers · 2016: 9 papers · 2017: 11 papers · 2018: 8 papers · 2019: 14 papers · 2020: 14 papers · 2021: 11 papers · 2022: 7 papers, 1 grant · 2023: 3 papers · 2024: 10 papers, 1 grant · 2025: 11 papers · 2026: 9 papers, 2 grants

Papers 50 of 141

  1. Association of obstructive sleep apnea with pancreatic cancer in high-risk patients under surveillance in CAPS and PCYST cohorts. Last author DOI 10.1016/j.pan.2026.10.013↗
  2. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  3. Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models. Co-author DOI 10.1038/s41698-026-01479-x↗
  4. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  5. Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-0331↗
  6. Fingerprinting the Metabolic and Lipidomic Landscapes of Pancreatic Ductal Adenocarcinoma with MALDI Imaging. Co-author DOI 10.1158/1078-0432.ccr-25-1115↗
  7. Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study. Last author DOI 10.1158/1078-0432.ccr-25-4061↗
  8. First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Co-author DOI 10.1158/2159-8290.cd-25-2245↗
  9. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  10. Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance-Reply. Last author DOI 10.1001/jamaoncol.2024.5522↗
  11. The Crosstalk with CXCL10-Rich Tumor-Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape. Co-author DOI 10.1002/advs.202417724↗
  12. A Mixed-Methods Approach to Assessing Barriers and Facilitators to Cancer Genetics Care in Black and Latino/a Individuals Impacted by Pancreatic Cancer: The Ra… Co-author DOI 10.1007/s10620-025-09018-7↗
  13. Mild Dilatation of the Main Pancreatic Duct Is a Risk Factor for Progression to Pancreatic Cancer in High-Risk Individuals. Co-author DOI 10.1016/j.gastha.2025.100802↗
  14. Reply to the Letter to the Editor regarding “Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early … Co-author DOI 10.1016/j.pan.2025.04.017↗
  15. Allelic effects on KLHL17 expression underlie a pancreatic cancer genome-wide association signal at chr1p36.33. Co-author DOI 10.1038/s41467-025-59109-2↗
  16. Artificial neural network detection of pancreatic cancer from proton (1H) magnetic resonance spectroscopy patterns of plasma metabolites. Co-author DOI 10.1038/s43856-024-00727-0↗
  17. Reversible chemoresistance of pancreatic cancer grown as spheroids. Co-author DOI 10.1080/1120009x.2024.2402177↗
  18. Impact of race, sex and age on the probability of pancreatic cancer among patients with newly diagnosed diabetes in a claims-based cohort. Co-author DOI 10.1136/bmjopen-2025-099488↗
  19. Personalizing CA125 Levels Using Tumor Marker Variants: A Case-Control Analysis of Diagnostic Performance for Pancreatic Cancer. Last author DOI 10.1158/1055-9965.epi-25-1050↗
  20. Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic. Last author DOI 10.1200/po-24-00494↗
  21. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. Last author DOI 10.1001/jamaoncol.2024.1930↗
  22. The role of biomarkers in the early detection of pancreatic cancer. Co-author DOI 10.1007/s10689-024-00381-4↗
  23. Twenty-five years of surveillance for familial and hereditary pancreatic ductal adenocarcinoma: Historical perspectives and introduction to the special issue. Last author DOI 10.1007/s10689-024-00404-0↗
  24. Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies. Co-author DOI 10.1016/j.pan.2024.10.012↗
  25. A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families… Co-author DOI 10.1053/j.gastro.2024.01.042↗
  26. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Co-author DOI 10.1097/sla.0000000000006094↗
  27. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-24-0096↗
  28. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. Last author DOI 10.1200/jco.23.01573↗
  29. Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery. Last author DOI 10.1245/s10434-024-14942-5↗
  30. ASO Author Reflections: Using a CA19-9 Tumor Marker Gene Test to Assess Outcome after Pancreatic Cancer Surgery. First author DOI 10.1245/s10434-024-14974-x↗
  31. Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer. Co-author DOI 10.1016/j.ccell.2023.09.008↗
  32. Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention. Last author DOI 10.1053/j.gastro.2023.02.012↗
  33. Screening for pancreatic cancer has the potential to save lives, but is it practical? Co-author DOI 10.1080/17474124.2023.2217354↗
  34. Endoplasmic stress-inducing variants in CPB1 and CPA1 and risk of pancreatic cancer: A case-control study and meta-analysis. Last author DOI 10.1002/ijc.33883↗
  35. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Last author DOI 10.1016/j.cgh.2020.11.006↗
  36. Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer. Last author DOI 10.1016/j.cgh.2021.10.008↗
  37. Familial Pancreatic Cancer. First author DOI 10.1016/j.gtc.2022.06.006↗
  38. Endoplasmic stress-inducing variants in carboxyl ester lipase and pancreatic cancer risk. Last author DOI 10.1016/j.pan.2022.08.004↗
  39. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. First author DOI 10.1053/j.gastro.2021.10.014↗
  40. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. Co-author DOI 10.1093/jnci/djac167↗
  41. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. Co-author DOI 10.1001/jamaoncol.2021.3701↗
  42. Pancreatic cancer pathology viewed in the light of evolution. Co-author DOI 10.1007/s10555-020-09953-z↗
  43. Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.03.015↗
  44. COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Last author DOI 10.1016/j.pan.2021.04.005↗
  45. Inherited Pancreatic Cancer Syndromes and High-Risk Screening. Last author DOI 10.1016/j.soc.2021.06.002↗
  46. A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. Co-author DOI 10.1038/s41416-021-01580-x↗
  47. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Co-author DOI 10.1093/ajcn/nqab217↗
  48. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001835↗
  49. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  50. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Co-author DOI 10.1158/1940-6207.capr-20-0642↗

Trials 1

  1. The Cancer of the Pancreas Screening-5 CAPS5)Study Principal investigator NCT02000089↗

Grants 5

  1. Personalizing biomarkers to improve pancreas surveillance R01CA313242↗
  2. Using markers to improve pancreatic cancer screening and surveillance: a multi-center study U01CA210170↗
  3. Using Markers to Improve Pancreatic Cancer Screening R01CA176828↗
  4. Core 2: Biospecimen/Pathology Core P50CA062924↗
  5. CAPS multicenter trial: Imaging and markers for pancreatic cancer screening AWARD pancan:2013-michael-goggins-md-caps-multicenter-trial-imaging-and-marke

Closest collaborators

The 25 strongest of 408 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ralph H. Hruban · 53 shared papers, 1 shared grant, 2011–2025 · strength 4.18
  2. Marcia Irene Canto · 33 shared papers, 2012–2026 · strength 4.17
  3. Alison P. Klein · 33 shared papers, 1 shared grant, 2011–2025 · strength 3.27
  4. Jin Peng He · 25 shared papers, 2017–2026 · strength 3.02
  5. Amanda L. Blackford · 18 shared papers, 2015–2026 · strength 2.62
  6. Randall E. Brand · 17 shared papers, 2016–2025 · strength 1.95
  7. Christopher Lee Wolfgang · 29 shared papers, 2011–2025 · strength 1.84
  8. Sapna Syngal · 19 shared papers, 2012–2025 · strength 1.74
  9. Anne Marie Lennon · 14 shared papers, 1 shared grant, 2013–2024 · strength 1.70
  10. Richard Andrew Burkhart · 12 shared papers, 2019–2026 · strength 1.65
  11. James R. Eshleman · 14 shared papers, 2011–2025 · strength 1.46
  12. Anirban Maitra · 14 shared papers, 1 shared grant, 2011–2026 · strength 1.46
  13. Nicholas Jason Roberts · 15 shared papers, 2012–2023 · strength 1.38
  14. Takeichi Yoshida · 7 shared papers, 2022–2026 · strength 1.26
  15. Elena M. Stoffel · 11 shared papers, 2016–2024 · strength 1.21
  16. Daniel A. Laheru · 11 shared papers, 2012–2026 · strength 1.18
  17. Jun Yu · 16 shared papers, 2012–2020 · strength 1.01
  18. Gloria M. Petersen · 14 shared papers, 2012–2024 · strength 1.00
  19. Laura DeLong Wood · 12 shared papers, 2015–2026 · strength 0.99
  20. Helena Saba · 4 shared papers, 2022–2025 · strength 0.95
  21. Elliot K. Fishman · 9 shared papers, 2014–2024 · strength 0.86
  22. Fay Kastrinos · 8 shared papers, 2019–2024 · strength 0.84
  23. Elham Afghani · 3 shared papers, 2025–2026 · strength 0.83
  24. Yohei Ando · 3 shared papers, 2024 · strength 0.83
  25. Elizabeth Abou Diwan · 4 shared papers, 2024–2026 · strength 0.82

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.